Adeno-Associated Virus (AAV) Vectors In Gene Therapy Market To Reach USD $7 Billion By 2030 At 17.5% CAGR

(MENAFN- EIN Presswire) EINPresswire/ -- Adeno-associated virus (AAV) vectors in gene therapy market to surpass $7 billion in 2030. In comparison, the Gene Therapy market, which is considered as its parent market, is expected to be approximately $36 billion by 2030, with Adeno-Associated Virus (AAV) Vectors in Gene Therapy to represent around 19% of the parent market. Within the broader Pharmaceuticals industry, which is expected to be $2,513 billion by 2030, the Adeno-Associated Virus (AAV) Vectors in Gene Therapy market is estimated to account for nearly 0.3% of the total market value.

Which Will Be The Biggest Region In The Adeno-Associated Virus (AAV) Vectors in Gene Therapy Market In 2030
North America will be the largest region in the adeno-associated virus (AAV) vectors in gene therapy market in 2030, valued at $2.8 billion. The market is expected to grow from $1.3 billion in 2025 at a compound annual growth rate (CAGR) of 16%. The rapid growth can be attributed to strong government and private funding for gene therapy research, a well-established biopharmaceutical and biotech ecosystem, growing clinical trial activities, increasing adoption of advanced gene therapy platforms, and the presence of leading gene therapy developers and contract manufacturing organizations across the United States and Canada.

Which Will Be The Largest Country In The Global Adeno-Associated Virus (AAV) Vectors in Gene Therapy Market In 2030?
The USA will be the largest country in the adeno-associated virus (AAV) vectors in gene therapy market in 2030, valued at $2.6 billion. The market is expected to grow from $1.2 billion in 2025 at a compound annual growth rate (CAGR) of 16%. The rapid growth can be attributed to a robust gene therapy ecosystem, significant investment in research and development, increasing FDA approvals for AAV-based therapies, rising prevalence of genetic disorders, expansion of clinical trials, and strong support from academic and biotech institutions across the country.

Request A Free Sample Of The Adeno-Associated Virus (AAV) Vectors In Gene Therapy Market Report

What Will Be Largest Segment In The Adeno-Associated Virus (AAV) Vectors in Gene Therapy Market In 2030?
The adeno-associated virus (AAV) vectors in gene therapy market are segmented by type of therapy into gene augmentation, immunotherapy, and other type of therapy. The gene augmentation market will be the largest segment of the adeno-associated virus (AAV) vectors in gene therapy market segmented by type of therapy, accounting for 63% or $4 billion of the total in 2030. The gene augmentation market will be supported by the increasing adoption of AAV-based therapies for rare genetic disorders, rising clinical trial activities, technological advancements in vector design and delivery, growing investment by biotech and pharmaceutical companies, and expanding regulatory approvals emphasizing safe and effective gene therapy outcomes.

The adeno-associated virus (AAV) vectors in gene therapy market are segmented by type of gene delivery method used into ex vivo, and in vivo.

The adeno-associated virus (AAV) vectors in gene therapy market are segmented by scale of operation into preclinical, clinical, and commercial.

The adeno-associated virus (AAV) vectors in gene therapy market are segmented by target therapeutic area into genetic disorders, hematological disorders, infectious diseases, metabolic disorders, ophthalmic disorders, muscle disorders, neurological disorders, and other target therapeutic area.

What Is The Expected CAGR For The Adeno-Associated Virus (AAV) Vectors in Gene Therapy Market Leading Up To 2030?
The expected CAGR for the adeno-associated virus (AAV) vectors in gene therapy market leading up to 2030 is 18%.

What Will Be The Growth Driving Factors In The Global Adeno-Associated Virus (AAV) Vectors in Gene Therapy Market In The Forecast Period?
The rapid growth of the global adeno-associated virus (AAV) vectors in gene therapy market leading up to 2030 will be driven by the following key factors that are expected to reshape gene therapy development pipelines, clinical trial methodologies, regulatory frameworks, manufacturing standards, and innovation across global biotechnology and pharmaceutical ecosystems.

Increasing Number Of Gene Therapy Clinical Trials And Approvals - The increasing number of gene therapy clinical trials and approvals is expected to become a key growth driver for the adeno-associated virus (AAV) vectors in gene therapy market by 2030. As biotechnology and pharmaceutical companies intensify research into gene-based treatments, the demand for efficient gene delivery systems such as AAV vectors continues to rise. Clinical trials rely heavily on viral vectors to transport therapeutic genes into patient cells, making AAV vectors a critical component in the development pipeline of gene therapies. The growing success rate of gene therapy studies and the approval of treatments for conditions such as inherited retinal diseases and spinal muscular atrophy have strengthened confidence in AAV-based platforms. These approvals also encourage further investment from pharmaceutical companies, research institutions, and venture capital firms. As more therapies move from early research stages into late-stage clinical trials and commercialization, the production and use of AAV vectors increase significantly. As a result, the increasing number of gene therapy clinical trials and approvals is anticipated to contribute to 3.0% annual growth in the market.

Rising Prevalence Of Rare And Genetic Disorders - The rising prevalence of rare and genetic disorders is expected to emerge as a major factor driving the expansion of the adeno-associated virus (AAV) vectors in gene therapy market by 2030. The rising prevalence of rare and inherited genetic disorders is another key factor driving the AAV vectors in gene therapy market. Many genetic diseases are caused by mutations or missing genes that cannot be effectively treated with traditional pharmaceuticals. Gene therapy offers a promising solution by delivering functional copies of genes directly into affected cells, and AAV vectors are widely used for this purpose due to their safety and efficiency. As awareness and diagnosis of rare diseases improve globally, healthcare systems and research organizations are focusing more resources on developing targeted therapies. Governments and regulatory agencies are also providing incentives such as orphan drug designations, research grants, and accelerated approval pathways to encourage the development of treatments for rare conditions. AAV vectors play a central role in many of these therapies because of their ability to enable long-term gene expression with relatively low immune response. Consequently, the rising prevalence of rare and genetic disorders is projected to contribute to around 2.7% annual growth in the market.

Advancements In Viral Vector Engineering And Manufacturing Technologies - The advancements in viral vector engineering and manufacturing technologies are expected to act as a key growth catalyst for the adeno-associated virus (AAV) vectors in gene therapy market by 2030. The Technological advancements in viral vector engineering and manufacturing are significantly accelerating the growth of the AAV vectors in gene therapy market. Continuous innovation in vector design has improved the efficiency, specificity, and stability of AAV vectors, enabling them to target specific tissues and deliver therapeutic genes more effectively. Scientists are developing new AAV serotypes and engineered capsids that enhance gene delivery to organs such as the liver, brain, muscles, and eyes. At the same time, improvements in manufacturing platforms, including scalable cell culture systems and advanced purification techniques, are helping increase vector yield and production efficiency. These developments reduce production bottlenecks and make it easier for companies to produce AAV vectors at a commercial scale for clinical and therapeutic use. Enhanced manufacturing technologies also support faster development timelines and improve product quality and consistency. As gene therapy research expands globally, these technological improvements strengthen the reliability and accessibility of AAV vectors, encouraging broader adoption across pharmaceutical and biotechnology companies developing next-generation genetic treatments. Therefore, the advancements in viral vector engineering and manufacturing technologies are projected to contribute to approximately 2.5% annual growth in the market.

Access The Detailed Adeno-Associated Virus (AAV) Vectors in Gene Therapy Market Report Here

What Are The Key Growth Opportunities In The Adeno-Associated Virus (AAV) Vectors in Gene Therapy Market In 2030?
The most significant growth opportunities are anticipated in the gene augmentation market, the immunotherapy market, and the other type of therapy market. Collectively, these segments are projected to contribute over $3.8 billion in market value by 2030, driven by increasing research and development in AAV-based gene therapies, rising clinical trials for rare genetic disorders, technological advancements in vector delivery systems, growing investment from biotech and pharmaceutical companies, and expanding regulatory support for innovative gene therapy solutions, fuelling transformative growth within the broader gene therapy industry.

The gene augmentation market is projected to grow by $2.4 billion, the immunotherapy market by $0.9 billion, and the other type of therapy market by $0.5 billion over the next five years from 2025 to 2030.

Learn More About The Business Research Company
The Business Research Company ( ) is a leading market intelligence firm renowned for its expertise in company, market, and consumer research. We have published over 17,500 reports across 27 industries and 60+ geographies. Our research is powered by 1,500,000 datasets, extensive secondary research, and exclusive insights from interviews with industry leaders.

We provide continuous and custom research services, offering a range of specialized packages tailored to your needs, including Market Entry Research Package, Competitor Tracking Package, Supplier & Distributor Package and much more.

Disclaimer: Please note that the findings, conclusions and recommendations that TBRC Business Research Pvt Ltd delivers are based on information gathered in good faith from both primary and secondary sources, whose accuracy we are not always in a position to guarantee. As such TBRC Business Research Pvt Ltd can accept no liability whatever for actions taken based on any information that may subsequently prove to be incorrect. Analysis and findings included in TBRC reports and presentations are our estimates, opinions and are not intended as statements of fact or investment guidance.

Contact Us:
The Business Research Company
Americas +1 310-496-7795
Europe +44 7882 955267
Asia & Others +44 7882 955267 & +91 8897263534
Email:...

Follow Us On:
LinkedIn: "

MENAFN06042026003118003196ID1110947711